Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
Goldman
John
J
Department of Hematology, Imperial College at Hammersmith Hospital, London, UK. goldmanj2@nhlbi.nih.gov
D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D001549:Benzamides; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000191:economics*; D010879:Piperazines / Q000191:economics* / Q000627:therapeutic use; D011743:Pyrimidines / Q000191:economics* / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D012189:Retrospective Studies; D016019:Survival Analysis
D000970:Antineoplastic Agents; D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate